Consequences, Opportunities and Challenges of Modern Biotechnology for Europe

01.04.2007

 

From the EU's Bio4EU Study carried out by the Joint Research Centre (April 2007)  

- Modern biotechnology and its applications generate almost 2% of EU gross value added, indicating that its importance is comparable to Europe’s largest industry sectors.

- The European dedicated biotechnology industry directly employs 96.500 people, mostly in SMEs; however given biotechnology’s “enabling effect”, employment in industries using biotechnology products is many times higher.

- Revenues for biotech vaccines jumped from EUR 65 million in 1996 to EUR 259 million.

- In the agro-industry, up to 20% of the input sector’s turnover is now related to biotech.

- In industrial biotech the EU produces about 75% of the world’s enzymes.

Read more on Bio 4 EU study website.

EuropaBio Explains the Bio4EU Study